3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Surgery
1
Stress, Psychological
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Seminoma
1
Sarcoma
1
Recurrence
1
Postoperative Complications
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
1
Multiple Myeloma
1
Medulloblastoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Intermittent Fasting
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Interventions
Rituximab
40
Cyclophosphamide
36
Prednisone
24
Doxorubicin
23
Magnetic Resonance Spectroscopy
20
Vincristine
19
Gemcitabine
18
Specimen Handling
17
Lenalidomide
17
Biopsy
15
Oxaliplatin
14
polatuzumab vedotin
13
obinutuzumab
11
glofitamab
11
ibrutinib
10
fludarabine
8
Etoposide
8
Dexamethasone
8
CT-P10
8
prednylidene
7
deltacortene
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
7
venetoclax
6
tafasitamab
6
pembrolizumab
6
Prednisolone
6
fludarabine phosphate
5
acalabrutinib
5
R-CHOP protocol
5
Immunotherapy, Adoptive
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
Neoadjuvant Therapy
×
90 days
×
Clear all
No trials found.